BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11752859)

  • 1. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
    Friedrich MG; Blind C; Milde-Langosch K; Erbersdobler A; Conrad S; Löning T; Hammerer P; Huland H
    Eur Urol; 2001 Nov; 40(5):518-24. PubMed ID: 11752859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the p16 and p15 genes in human bladder tumors.
    Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
    J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
    Friedrich MG; Riethdorf S; Erbersdobler A; Tiemer C; Schwaibold H; Sölter JK; Huland E; Riethdorf L; Conrad S; Hammerer PG; Huland H
    Eur Urol; 2001 Feb; 39(2):159-66. PubMed ID: 11223675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
    Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
    J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
    Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
    Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder.
    Kimura F; Florl AR; Seifert HH; Louhelainen J; Maas S; Knowles MA; Schulz WA
    Br J Cancer; 2001 Dec; 85(12):1887-93. PubMed ID: 11747331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers.
    Okajima E; Fukuda T; Okita S; Tsutsumi M; Hirao Y; Okajima E; Konishi Y
    Cancer Lett; 1996 Jun; 103(2):227-31. PubMed ID: 8635161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
    Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
    Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder.
    Edwards J; Duncan P; Going JJ; Watters AD; Grigor KM; Bartlett JM
    J Pathol; 2002 Apr; 196(4):380-5. PubMed ID: 11920732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
    Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
    Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
    Gorgoulis VG; Koutroumbi EN; Kotsinas A; Zacharatos P; Markopoulos C; Giannikos L; Kyriakou V; Voulgaris Z; Gogas I; Kittas C
    Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma.
    Ko JY; Lee TC; Hsiao CF; Lin GL; Yen SH; Chen KY; Hsiung CA; Chen PJ; Hsu MM; Jou YS
    Cancer; 2002 Apr; 94(7):1987-96. PubMed ID: 11932901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
    Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The mechanism of p16 gene inactivation in human bladder transitional cell carcinoma].
    Wu Y; Wu H; Ma T; Wu C
    Zhonghua Bing Li Xue Za Zhi; 1999 Feb; 28(1):39-41. PubMed ID: 11869511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
    J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder.
    Erbersdobler A; Friedrich MG; Schwaibold H; Henke RP; Huland H
    Oncol Res; 1998; 10(8):415-20. PubMed ID: 10100758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.